Gene Therapy Market - Forecasts from 2019 to 2024
The global gene therapy market is expected to grow at a CAGR of 16.92% reach $8.748 billion by 2024 from $3.425 billion in 2018. Gene therapy is an experimental technique that involves the introduction of DNA usually containing a functional gene t into a patient for the treatment of genetic disorders. Gene therapy works by replacing, repairing or repressing the mutated gene. Therefore, with the right target and approach, it can address the root cause of a severe disease where known genetic mutations lead to deficient or non-functional protein production or other related problems. The gene therapy may be a promising option for genetic diseases such as muscular dystrophy and cystic fibrosis.
The growth in the market may be attributed to the increase in awareness among the people regarding the benefits of gene therapy coupled with the increased funding activities for research and development of gene therapy by various governments. However, the high cost of gene therapy might restrain the growth of the market during the given forecast period. Problems with suppressing the immune responses due to the introduction of new genes may also hamper the market growth during the given time frame.
The Global Gene Therapy Market – Forecasts from 2019 to 2024” is an exhaustive study that aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by Technique, Vector Type, Indication and geography.
Based on the technique, the market has been segmented as gene augmentation, gene inhibition, and killing of specific cells. On the basis of the vector type, the global gene therapy market is segmented as viral vectors and non-viral vectors. Indications of the global gene therapy market include Genetic Disorders, Cardiovascular and Oncology and Others.
Regional analysis has been provided with detailed analysis and forecast for the period 2019 to 2024. The global market has been broken down into North America, South America, Europe, Middle East and Africa, and the Asia Pacific regions. The report also analyzes major countries across these regions with thorough analysis and forecast along with prevailing market trends and opportunities which each of these countries present for the manufacturers.
Major players in the gene therapy market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the gene therapy market.
Segmentation:
The growth in the market may be attributed to the increase in awareness among the people regarding the benefits of gene therapy coupled with the increased funding activities for research and development of gene therapy by various governments. However, the high cost of gene therapy might restrain the growth of the market during the given forecast period. Problems with suppressing the immune responses due to the introduction of new genes may also hamper the market growth during the given time frame.
The Global Gene Therapy Market – Forecasts from 2019 to 2024” is an exhaustive study that aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by Technique, Vector Type, Indication and geography.
Based on the technique, the market has been segmented as gene augmentation, gene inhibition, and killing of specific cells. On the basis of the vector type, the global gene therapy market is segmented as viral vectors and non-viral vectors. Indications of the global gene therapy market include Genetic Disorders, Cardiovascular and Oncology and Others.
Regional analysis has been provided with detailed analysis and forecast for the period 2019 to 2024. The global market has been broken down into North America, South America, Europe, Middle East and Africa, and the Asia Pacific regions. The report also analyzes major countries across these regions with thorough analysis and forecast along with prevailing market trends and opportunities which each of these countries present for the manufacturers.
Major players in the gene therapy market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the gene therapy market.
Segmentation:
- By Technique
- Gene Augmentation
- Gene Inhibition
- Killing of specific cells
- By Vector Type
- Viral Vectors
- Non-Viral Vectors
- By Indication
- Genetic Disorders
- Cardiovascular
- Oncology
- Others
- By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- UK
- Germany
- Italy
- Spain
- Others
- Middle East and Africa (MEA)
- Israel
- Saudi Arabia
- Others
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- Others
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. GENE THERAPY MARKET BY TECHNIQUE
5.1. Gene Augmentation
5.2. Gene Inhibition
5.3. Killing of specific cells
6. GENE THERAPY MARKET BY VECTOR TYPE
6.1. Viral Vectors
6.2. Non-Viral Vectors
7. GENE THERAPY MARKET BY INDICATION
7.1. Genetic Disorders
7.2. Cardiovascular
7.3. Oncology
7.4. Others
8. GENE THERAPY MARKET BY GEOGRAPHY
8.1. North America
8.1.1. USA
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. UK
8.3.2. Germany
8.3.3. Italy
8.3.4. Spain
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Israel
8.4.2. Saudi Arabia
8.4.3. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. Australia
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Competitive Benchmarking and Analysis
9.2. Strategies of Key Players
9.3. Recent Investments and Deals
10. COMPANY PROFILE
10.1. Novartis
10.2. Amgen
10.3. Bluebird Bio
10.4. Glaxosmithkline
10.5. Shenzhen Sibiono Genetech
10.6. Spark Therapeutics
10.7. AveXis, Inc.
10.8. Chiesi Farmaceutici
10.9. Alnylam
List of Figures
List of Tables
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. GENE THERAPY MARKET BY TECHNIQUE
5.1. Gene Augmentation
5.2. Gene Inhibition
5.3. Killing of specific cells
6. GENE THERAPY MARKET BY VECTOR TYPE
6.1. Viral Vectors
6.2. Non-Viral Vectors
7. GENE THERAPY MARKET BY INDICATION
7.1. Genetic Disorders
7.2. Cardiovascular
7.3. Oncology
7.4. Others
8. GENE THERAPY MARKET BY GEOGRAPHY
8.1. North America
8.1.1. USA
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. UK
8.3.2. Germany
8.3.3. Italy
8.3.4. Spain
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Israel
8.4.2. Saudi Arabia
8.4.3. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. Australia
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Competitive Benchmarking and Analysis
9.2. Strategies of Key Players
9.3. Recent Investments and Deals
10. COMPANY PROFILE
10.1. Novartis
10.2. Amgen
10.3. Bluebird Bio
10.4. Glaxosmithkline
10.5. Shenzhen Sibiono Genetech
10.6. Spark Therapeutics
10.7. AveXis, Inc.
10.8. Chiesi Farmaceutici
10.9. Alnylam
List of Figures
List of Tables
